Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery Platform
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Collaboration
Totus Medicines Announces Strategic Multi-Target Research Collaboration with Lilly
Details : Under the terms of the agreement, Totus Medicines will use its proprietary OmniDEL platform to discover small molecule drug candidates against Lilly's undisclosed targets.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 16, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Collaboration
Totus Medicines Closes $66M Series B to Fund Early-Stage PI3Ka Inhibitor, Names New CEO
Details : The net proceeds will be used for the advancement of company's pipeline of clinical candidates led by TOS-358, a covalent inhibitor of PI3Ka for the treatment of adults with select solid tumors.
Product Name : TOS-358
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 15, 2023
Details : TOS-358 is the company's first-in-class covalent, highly specific, potent PI3Kα inhibitor for the treatment of numerous cancers with known PIK3CA mutations.
Product Name : TOS-358
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 13, 2023
Lead Product(s) : TOS-358
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Totus Medicines CEO to Present at Next-Generation Undruggable Conference
Details : TOS-358, the first highly selective covalent molecule targeting PI3Kα, which is the most mutated oncogene in cancer, induces stasis and regression across PI3Kα mutant models.
Product Name : TOS-358
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 10, 2022
Lead Product(s) : TOS-358
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TOS-358
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TOS-358 is a highly selective covalent inhibitor of PI3Kα. TOS-358 demonstrates clear superiority compared to non-covalent molecules by achieving deep and durable inhibition of PI3K-AKT signaling.
Product Name : TOS-358
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 27, 2022
Lead Product(s) : TOS-358
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TOS-358
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : DCVC Bio
Deal Size : $40.0 million
Deal Type : Series A Financing
Totus Medicines Emerges from Stealth with Revolutionary Drug Program Targeting PI3K-Alpha Oncogene
Details : The Series A financing will be used to expand and scale Totus Medicines' proprietary drug discovery platform and advance the company's TOS-358 drug program targets the PI3K? mutation into the clinic.
Product Name : TOS-358
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 12, 2021
Lead Product(s) : TOS-358
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : DCVC Bio
Deal Size : $40.0 million
Deal Type : Series A Financing